Researchers at Stanford University have made a groundbreaking discovery in appetite control with a molecule named BRP, which operates through a unique biological pathway. This innovative compound activates specific neuron groups in the brain, suggesting a more targeted method for regulating appetite and metabolism.
According to Dr. Katrin Svensson, an assistant professor of pathology, "The receptors that semaglutide targets are located in both the brain and various other organs, which accounts for its broad effects, including delaying food movement in the digestive system and lowering blood sugar levels. In contrast, BRP seems to work specifically within the hypothalamus, the brain region responsible for appetite and metabolic regulation."
This research, published in the journal Nature, highlights the collaborative efforts of Dr. Svensson and senior research scientist Dr. Laetitia Coassolo, who is leading the charge towards human clinical trials through their newly founded company.
The Role of Artificial Intelligence in Discovery
The identification of BRP was significantly aided by artificial intelligence, which analyzed a vast array of prohormones--initially inactive molecules that can be cleaved into smaller peptide fragments, some of which are crucial for hormonal functions affecting metabolism.
Traditional lab techniques often struggle to isolate these valuable peptide hormones from the inactive fragments generated during protein degradation. To streamline their search, the team concentrated on an enzyme known as prohormone convertase 1/3, associated with obesity and involved in producing glucagon-like peptide 1 (GLP-1), a key player in appetite and blood sugar regulation.
Introducing the Peptide Predictor
Instead of conventional protein analysis, the researchers created a tool called Peptide Predictor, which scanned all 20,000 human protein-coding genes to pinpoint potential cleavage sites for prohormones. This approach narrowed the list down to 373 prohormones suitable for further investigation.
From these candidates, the algorithm predicted 2,683 possible peptides, leading to the selection of 100 for testing on lab-grown brain cells.
BRP: A Small Peptide with Significant Impact
While GLP-1 enhanced neuronal activity, BRP--a much smaller peptide consisting of only 12 amino acids--demonstrated an even more profound impact, amplifying activity tenfold compared to control groups.
In animal studies involving lean mice and minipigs, BRP notably decreased food intake, with a single injection before feeding cutting consumption by up to 50%. In obese mice, daily injections over two weeks resulted in an average weight loss of 3 grams, primarily from fat, while untreated counterparts gained weight.
A New Frontier in Weight Management
The research team is now focused on identifying the specific receptors that interact with BRP and improving its efficacy for potential human use. Dr. Svensson expressed optimism, stating, "The search for effective obesity treatments has been challenging for years. We are excited to see if BRP proves safe and effective in humans."
With contributions from various institutions and funding from the National Institutes of Health and other organizations, this discovery represents a promising step forward in metabolic health and weight management.
